TriangleNCT00934544 · OUTCOME
Overall Survival (OS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Years
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From randomization until death from any cause
What was measured
Defined as the interval between randomization and the date of the bone marrow blast count of 20% or greater OR the date of the first peripheral blast count of 20% or greater that was subsequently confirmed to have been sustained for at least 8 weeks OR the date of death from any cause, whichever occurs first. OS was summarized using Kaplan-Meier estimates for each treatment arm. The estimates were supplemented by tables of number of events and probability estimates at several timepoints
Analysis population: Full analysis set (FAS) consisted of all subjects who were randomized and put in strata according to International Working Group for Myelofibrosis Research and Treatment(IWG MRT) prognostic criteria. Treatment groups were defined according to the treatment assignment at the time of randomization.
Groups in this outcome
Ruxolitinib
5 milligram tablets administered orally in an outpatient setting according to the protocol-specified dosing schedule
Best Available Therapy (BAT)
Commercially available therapy, oral or parenteral, per manufacturer's instructions and Investigator discretion. BAT included the option of no treatment.
| Group | Source count |
|---|---|
| Ruxolitinib | 146 |
| Best Available Therapy (BAT) | 73 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Ruxolitinib | NA | Not reported | NA | NA | Values are not estimable as Median was not reached |
| Best Available Therapy (BAT) | 4.1 | Not reported | 2.4 | NA | Upper limit of CI was not estimable |
Complete source fields
- classes
- categories
- measurements
- comment
- Values are not estimable as Median was not reached
- group Id
- OG000
- lower Limit
- NA
- upper Limit
- NA
- value
- NA
- comment
- Upper limit of CI was not estimable
- group Id
- OG001
- lower Limit
- 2.4
- upper Limit
- NA
- value
- 4.1
- denoms
- counts
- group Id
- OG000
- value
- 146
- group Id
- OG001
- value
- 73
- units
- Participants
- description
- Defined as the interval between randomization and the date of the bone marrow blast count of 20% or greater OR the date of the first peripheral blast count of 20% or greater that was subsequently confirmed to have been sustained for at least 8 weeks OR the date of death from any cause, whichever occurs first. OS was summarized using Kaplan-Meier estimates for each treatment arm. The estimates were supplemented by tables of number of events and probability estimates at several timepoints
- dispersion Type
- 95% Confidence Interval
- groups
- description
- 5 milligram tablets administered orally in an outpatient setting according to the protocol-specified dosing schedule
- id
- OG000
- title
- Ruxolitinib
- description
- Commercially available therapy, oral or parenteral, per manufacturer's instructions and Investigator discretion. BAT included the option of no treatment.
- id
- OG001
- title
- Best Available Therapy (BAT)
- param Type
- MEDIAN
- population Description
- Full analysis set (FAS) consisted of all subjects who were randomized and put in strata according to International Working Group for Myelofibrosis Research and Treatment(IWG MRT) prognostic criteria. Treatment groups were defined according to the treatment assignment at the time of randomization.
- reporting Status
- POSTED
- time Frame
- From randomization until death from any cause
- title
- Overall Survival (OS)
- type
- SECONDARY
- unit Of Measure
- Years
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice